192 related articles for article (PubMed ID: 20516565)
1. Molecular genesis of drug-resistant and vaccine-escape HBV mutants.
Locarnini SA; Yuen L
Antivir Ther; 2010; 15(3 Pt B):451-61. PubMed ID: 20516565
[TBL] [Abstract][Full Text] [Related]
2. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
Locarnini S; Warner N
Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
[TBL] [Abstract][Full Text] [Related]
3. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.
Teo CG; Locarnini SA
Antivir Ther; 2010; 15(3 Pt B):445-9. PubMed ID: 20516564
[TBL] [Abstract][Full Text] [Related]
4. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
Sayan M; Akhan SC
Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
[TBL] [Abstract][Full Text] [Related]
5. Molecular virology and the development of resistant mutants: implications for therapy.
Locarnini S
Semin Liver Dis; 2005; 25 Suppl 1():9-19. PubMed ID: 16103977
[TBL] [Abstract][Full Text] [Related]
6. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.
Lacombe K; Boyd A; Gozlan J; Lavocat F; Girard PM; Zoulim F
Antivir Ther; 2010; 15(3 Pt B):493-7. PubMed ID: 20516570
[TBL] [Abstract][Full Text] [Related]
7. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
Yeh CT
Antivir Ther; 2010; 15(3 Pt B):471-5. PubMed ID: 20516567
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus mutations associated with antiviral therapy.
Bartholomeusz A; Locarnini S
J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus escape mutants induced by antiviral therapy.
Sheldon J; Soriano V
J Antimicrob Chemother; 2008 Apr; 61(4):766-8. PubMed ID: 18218641
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetics of HBV infection.
Locarnini S; Zoulim F
Antivir Ther; 2010; 15 Suppl 3():3-14. PubMed ID: 21041899
[TBL] [Abstract][Full Text] [Related]
12. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus genetic diversity.
Echevarría JM; Avellón A
J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus resistance to nucleos(t)ide analogues.
Zoulim F; Locarnini S
Gastroenterology; 2009 Nov; 137(5):1593-608.e1-2. PubMed ID: 19737565
[TBL] [Abstract][Full Text] [Related]
15. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
[TBL] [Abstract][Full Text] [Related]
16. Viral and clinical factors associated with surface gene variants among hepatitis B virus carriers.
Roque-Afonso AM; Férey MP; Ly TD; Graube A; Costa-Faria L; Samuel D; Dussaix E
Antivir Ther; 2007; 12(8):1255-63. PubMed ID: 18240865
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries.
Basuni AA; Butterworth L; Cooksley G; Locarnini S; Carman WF
Vaccine; 2004 Jul; 22(21-22):2791-9. PubMed ID: 15246613
[TBL] [Abstract][Full Text] [Related]
18. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.
Torresi J; Earnest-Silveira L; Deliyannis G; Edgtton K; Zhuang H; Locarnini SA; Fyfe J; Sozzi T; Jackson DC
Virology; 2002 Feb; 293(2):305-13. PubMed ID: 11886250
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
